August 16, 2023
Publisher's Note
32
7/8
Increased adoption of decentralized trials and new advancements in technology among reasons for evolving regulatory landscape.
August 16, 2023
Feature Articles
32
7/8
Stepped-up training and real-time application key to avoiding compliance pitfalls.
August 15, 2023
Feature Articles
32
7/8
How to support trial investigators through decentralization of trial elements.
August 14, 2023
From the Editor
32
7/8
Agency provides update on decentralized trials and digital health technologies at DIA 2023.
August 14, 2023
Feature Articles
32
7/8
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
August 11, 2023
Data Collection
32
7/8
eCOA and PRO consortiums along with regulators gather for discussion on important data collection topics.
July 31, 2023
Q&A
32
7/8
In this Q&A, Dodd speaks about GeoVax's vaccine development strategy, clinical trials, and approach to serving patient populations often overlooked by conventional vaccines.
July 28, 2023
View from Brussels
32
7/8
A look at the complexities—and potentially conflicting goals—in industry’s commitment to trial-result transparency.
July 21, 2023
View from Washington
32
7/8
The agency proposes significant revisions to oversight programs for drugs and medical products.
June 16, 2023
A Closing Thought
32
7/8
Changing the expectations of the feasibility study can improve the process.